afternoon at Good we our turn quarter. significant a focused of strategic managed companies excited potential. joining aimed actively the operating us. recent overview Jody. Slide as with X, revenue Thanks and for thanks to brief our by building at I’m PDL of everyone Biopharma progress for Please shift execute portfolio of
million investment Evofem have Indeed a we Biosciences. $XX highlight of is where about the second a completion position significant quarter taken equity in a
the leader health. of the We to Amphora of management flagship support goal team are the building Evofem’s with launch to a the in experienced into committed successful product company women's with working ultimate
approximately the received. our at the our which reporting gain of value on price of $XX the a from $X.XX quarter of price share of Evofem‘s the quarter, revenues a we result closing investment end are the stock and investment For appreciation increased the the million, per to second stock is non-cash of of
are a LENSAR AcelRx adoption than slower the of of of assets, performance on non-cash from fair was negatively of royalty shifting Zalviso, companies, operating it of the It and regard and the with importance rights, to Europe We XXXX launched the assets. by revenue our execution as our value to was legacy pleased quarter their underlines With both Noden model down result are write of with since of managed actively market business which by expected is disappointing impacted the passive investment plan. the the for Grünenthal. continued in target our
streamline including are balance to our regard our assets. and working sheet considering with option to are underperforming We exit our strategies legacy
to from asset continue receive significant cash execute and on our business have hand royalty strategy. Assertio We to royalty ample on
thereby in We our excess needs, invest expect cash future. generated our in operational be additional current to of our cash will flow business by providing
We range to potential to build and numerous our transactions continue review of opportunities consider a portfolio. broad
serving Board Development, address Dr. as Vice observer. it novel role therapeutics our enabling X, appointed Jene I those significant as Turning active have underserved as potential to assume has the transaction companies our board potential Amphora, an the to like our see that sizeable of with with strategic Business In We shareholders address strategy, President a market opportunity. for PDL partner to Slide of a revenue patients and is Evofem been strong Directors of mission fit keeping Jill creating of a by is Evofem value maximize needs. our for and
of be leadership to working with will for Amphora. the approval build the Evofem’s term, to near and file support FDA infrastructure a launch strong we In commercial successful
health large health ultimate both undeserved have medical company. in [indiscernible] the area significant an by view of the bringing novel to of achieving that some industry in We it interest presents goal women's unmet board been building the solutions because are leader to pharmaceutical advance strategic an highly of company needs as women. the aligned We with mean
As in in shares the more second million under the approximately in the agreement. PDL of a turn XX% Evofem the brief overview closing million or PDL stock investor trenches second common of in $XX of second closing largest two XX.X PDL transaction was with Evofem of securities close the with $XX The outstanding total agreement the June. the April million X. tranche, and terms, was first to please Slide structured with shares. At with of a invested than
months the seven We the also issuance for hold to more us beginning time. date, the stock six after exercisable warrants for increase years, option X.X than giving common million Evofem ownership
and to Evofem. acidic the Evofem prevention to spermatozoa designed preventing in gel or our Vaginal on-demand supporting investigational, X, decision bio-adhesive want pH a I share has properties. natural vaginal factors Regulator in investment MVP-R is of of inhibiting pregnancy. Multipurpose Slide a while Turning motility to innovative, with to of survival acid-buffering X.X It maintain X.X an multiple pH
and Earlier reported additional on women's analysis the endpoint safety has lives. a Results week, X by AMPOWER makes December of studies Evofem that profile, of Evofem XXXX, for that and suggesting this the Phase an of improve use Amphora’s for prevention Amphora Amphora pregnancy Amphora, in of primary shows a at well-tolerated. sex were positive sexual exploratory and was called endpoint reported favorable satisfaction impact and
AMPOWER effects sexual to is study a explore candidate the satisfaction. of contraceptive product first clinical on the
pregnant. active cannot, estimated opportunity. a contraception, use As million considerable serve. not women primary a U.S. market not are hormonal on-demand using that an do the will a is sexually expected includes contraceptive, contraceptive to is XX women which to population method alone, and are or non-hormonal, Amphora not In who addresses and Amphora become This want
important decision women Amphora most or the the who currently about XX% the the and use are women the non-hormonal concerned surveyed of also hormones. to contraception important hormonal in that future. side appeal extremely the study, impact the Amphora in may to are long-term the Amphora, but using of AMPOWER effects said the aspects are Of to
of that year. recently of and result gonorrhea. track completed XXX a enrollment Evofem of and is through believe We've reimbursed of to Amphora acidic they standpoint, or in environment U.S. we endpoint be will in widely Amphora’s prevention for Care the Act. payers' chlamydia gonorrhea. label report requirements the such patients microbes co-pay the indisputable low recently to Affordable prevention has a top to the a that is Amphora landmark chlamydia secondary trial. ability of this in on clinical X create that holds of gone due its to Phase contraception as to November And as line confirmed standalone method expansion it From potential no also positive with with
in important prevention note U.S. products of It to one indicated most sexually no there of is positive are transmitted that infection for common chlamydia, the the the
Importantly, commercial designed that the covers maximize contraceptive XX% of Evofem commercial products prescribers launch months salesforce advertising strategy of prevention has well defined for pregnancy. of try to our nine direct-to-consumer assembling post to to Amphora top This six initiate and include a strategy within
passion chlamydia. the Amphora’s prevention the team all pre-commercial management commencement balance of prevention succeed. and of NDA Evofem more which is And brings as with in has quarter extensive completion Phase strong activities include Xb last, than to the of resubmission pregnancy, for fund event the This cash study million $XX expected second for the of and Evofem for and planned XXXX. of the sheet a of to June activities are the XX, experience
price quarter. to shareholder non-cash at carry how this fair close Turning our million with of in so based value investment, value each investment The do the gain Evofem Slide as value our of X, of is we reflected quarter. create this at in investment stock of we the $XX.X fair on the
of the Amphora the of line pregnancy AMPREVENCE the the for the of we of Amphora quarter endpoint we treatment In NDA Phase use for expect with to on Evofem fourth of in XXXX. gonorrhea excited near-term of are share The that quarter expected of trial of number prevention of top catalysts terms include is prevention of XXXX. for also Xb would secondary fourth the the release the it price for chlamydia prevention of evolution, the resubmission about of data
Amphora U.S., prevention the to approval, which first XXXX. which date expected the half XXXX second in commercial expected and is PDUFA is the of the subject The half of of FDA launch in Amphora for for pregnancy in of
execute positively PDL’s impact we stock Evofem appreciate time, the the will in price price. strategy, they their turn this expect on as stock Over confident that are we
Moving X continue positioned we to well strategy. onto Slide PDLs are executing business our
generate with flow a AcelRx $XXX have that the liquid balance to to cash million sheet recent continue to you rights We expect $XXX in cash even in forecast. are adjustment royalty with million XXXX through with royalty along
are finding strict additional for business As We expect personal maximize generated will invest financial our management our in that ourselves of future. with our excess of flow operating a needs, by strategic be mentioned, current our expenses. investments providing cash cash to we thereby resources to in
range a PDL edge continue We in our number sheet believe to liquid that to broad we in deploy building our the of allows factors balance a funds. the which consider portfolio. of There us numerous executing of quickly are opportunities, an including investment review opportunities these and options necessary
all negotiating speed will Evofem deal experience of in the agreement. completion role a parties credible the structures Securities the involved. these negotiation Our our flexibility and in All and played us factors successful optimal in enable to of be
products, from capital assets that the with and pursuing, on. build our seeking we commercial transaction from and can stage In expertise terms collaborative quality late-state innovative high teams assets are of differentiating transfer are benefit we can accessing we
high that therapies compete all commercially the categories ability sales target with of considering unmet in focused underserved areas team. to with are We need
on structures be that focusing seeking return we engaged. are preference opportunity our as and the We U.S. enable the actively market geographic attractive are to and
our average million three repurchase programs by $XXX price repurchase $X.XX Slide share Under our XX shares billion million shares share. at an completed this used on we repurchased repurchase completed a share. approximately per In X. stock $X.XX XXXX, we Over an program share in board program July, to average we now $XXX of total authorized Turning program million September. price to XXXX our XX.X of last at in per repurchase since
with XXXX me one quarter from these increased increase over the System to Slide XXXX, of and year $X.X of surgery globally and XXXX. the the was a revenue second number cataract LENSAR of XX. the first which first million, period quarter from the Let X% increases now the a XX% Laser XX% revenues companies. by refractive growth increase outside is Product are the our portfolio quarter second potential U.S. primarily review significant procedure LENSAR XXXX, from volume had Starting a quarter Procedural market, on due surgical of in the during current from by XX% LENSAR volume. of
clear implanting greater of choice that leader laser a LENSAR the becoming accuracy surgeons is and require in customization. for and procedure it lenses innovation is cataract surgery intraocular
coming the LENSAR for continues further expanded position in out enhancing increase We approval by expect XXX(k) seeking to R&D technology quarters its of indications. leadership efforts its to and build the additional
the is Tekturna into Now in turning Pharma partner authorized and maximizing profitability XX. of increasing of Slide generic impact year. the distributing by focused to Noden of value began Tekturna Rasilez version competition. of and generic Noden this Laboratories an mitigating Prasco U.S. March on
effective share the at the Our Tekturna authorized first is strategy XXXX. of market and of XX% [indiscernible] proving captured end Tekturna of Prasco’s quarter generic market as a second two Branded U.S.
has not To Given and result half that generic quarter net in initial all product sees quarter by loss in the will to manufacturer, do the the Anchen. $X.X second second to and Noden of launch in Noden competition first further a net both of generic expect Noden efforts XXXX compared This beyond product profitability quarter, modest for restructured showed shipment team. aliskiren Tekturna with difficult million the additional is promotional third-party the expense U.S. this included expensive which of year the Prasco. maximize XXXX. for second in the we of income savings
income Noden six net was $X.X million. of the XXXX For first of months with profitable
and and of Seattle Pete our additional to and Directors. Corporate She is financial, member on and Executive in the our PDL Senior Natasha next will of week. experience Development M&A I'd years call want entire Board Today his past thanks the quarterly And PDL six my our details welcome brings firm's a to that executing final extend [indiscernible] of provide CFO. I to and Pete Genetics Before Vice over successfully with is us evaluating board to at for our Natasha behalf heartfelt Hernday Garcia his our Committee. as Board leaving of to be like president contribution on transaction. he team many
We professional Leadership this search to into state are for our conducting position Team essential a Senior on
Pete will financial our Pete. now review results.
